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Genome Law and PolicyMany patents make claims on DNA sequences; some include claims on oligonucleotides related to the
primary patented gene. We used bioinformatics to quantify the reach of one such claim from patent
4,747,282 on BRCA1. We ﬁnd that human chromosome 1 (which does not contain BRCA1) contains over
300,000 oligonucleotides covered by this claim, and that 80% of cDNA and mRNA sequences contributed to
GenBank before the patent application was ﬁled also contain at least one claimed oligonucleotide. Any
“isolated” DNA molecules that include such 15 bp nucleotide sequences would fall under the claim as
granted by the US Patent and Trademark Ofﬁce. Anyone making, using, selling, or importing such a molecule
for any purpose within the United States would thus be infringing the claim. This claim and others like it turn
out, on examination, to be surprisingly broad, and if enforced would have substantial implications for
medical practice and scientiﬁc research.Immunology, 2424 Erwin Rd,
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.In 1998, the US Patent and Trademark Ofﬁce granted Mark H.
Skolnick and ten of his collaborators a patent on the human gene
BRCA1 (US Patent 5,747,282). Mutations in BRCA1 confer a substantial
risk for breast and ovarian cancers, with a cumulative risk of incidence
by age 70 of 69% (breast) and 39% (ovarian) [1]. Genetic tests to screen
for these mutations in the United States are available exclusively
through Myriad Genetics, the assignee of the patent. Women with a
family history of breast and ovarian cancer may, through this genetic
test, determine whether they carry one of the high-risk alleles, and if
so, decide whether to take prophylactic action, including surgical
removal of breasts, ovaries or both.
Human gene patents are controversial [2]; BRCA1 patents are
currently the subject of litigation [3], and ’282 is among seven BRCA
patents named in a complaint ﬁled by the American Civil Liberties
Union that is now being litigated in federal court. A hearing in the
Southern district federal court of New York took place September 30,
2009, before Judge Robert W. Sweet [4]. On November 2, he released
an 88-page decision to continue the case [5], and heard oral
arguments on February 2, 2010 [6].
The patent itself is complex and makes several different claims.
One of these claims seemed to us particularly broad, so we
investigated it, doing simple calculations to estimate its reach, and
testing our ﬁndings by direct analysis of the extent of its reach within
parts of the human genome. We ﬁnd that, through this claim, thepatent extends to portions of most genes in the human genome and
likely to most genes in nature as well.
The patent ﬁrst makes claim 1, to “An isolated DNA coding for a
BRCA1 polypeptide, said polypeptide having the amino acid sequence
set forth in SEQ ID NO:2.” SEQ ID NO:2 is the 1863-residue amino acid
sequence for the protein encoded by the BRCA1 gene. The patent
further claims “5. An isolated DNA having at least 15 nucleotides of the
DNA of claim 1.” Note that claim 1 is DNA coding for the polypeptide,
not for any speciﬁc gene. There are, of course, many polynucleotides
that would encode the BRCA1 polypeptide. Claim 5, then, is a claim on
any 15-mer oligonucleotide found in any such sequence. We estimate
that the human genome contains over one million oligonucleotides
covered by this claim, and that most human genes contain at least one
and usually several oligonucleotides covered by the claim.
To estimate the breadth of this claim, one can perform a short
computation. Accounting for bias in the usage of amino acids as
reported, for example, in [7], the usage-weighted geometric mean
codon degeneracy per amino acid is 3.107. Therefore, the mean
number of 15-mers encoding a polypeptide of length 5 chosen at
random from a vertebrate proteome is 3.1075, about 290. There are
5,575 15-mers in BRCA1, so, if we consider all of the nucleotide
sequences that encode the BCRA1protein, there are about 1.6×106 15-
mers embodied by the claim. There are 415=1.07×109 different 15-
mers altogether, so the probability that a 15-mer chosen at random
will be covered by the claim is p=1.6×106 / 1.07×109=0.0015
(roughly, 1 in 600 possible 15-mers). A typical human gene (before
RNA editing) contains 10,000 bases, so, if human genes were random
strings of nucleotides, one would expect a human gene to contain an
average of 15 15-mers claimed under the patent.
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number of claimed 15-mers in a representative sample of the human
genome to test the breadth of claim 5 empirically. We examined
chromosome 1 (NCBI build 37.1), and counted only a subset of
claimed 15-mers. The reason for counting only a subset is that there
are three amino acids (serine, leucine, and arginine) that have 6-fold
degeneracy. If we neglect two of the six synonymous codons for each
of these amino acids, each degenerate 15-mer can be represented as a
single string of 15 letters, with degenerate positions encoded by the
extended IUPAC nucleotide alphabet. This representation permits a
many-fold reduction in computing time that will slightly understate
the degree of redundancy and breadth of claim 5.
Examining only this subset, we ﬁnd over 340,000matches of claimed
15-mers to the 250 million base pairs of chromosome 1, for an empirical
hit rate ofpemp=0.00136per15-mer, close toour theoretical expectation.
Using this estimate, we expect about 14 infringing sequences per human
gene, just one fewer than the 15 sequences per gene predicted above
based on assumption of random sequence strings.
The claims being discussed are structural, that is, claims to DNA
molecules, and do not restrict acts of infringement to particular uses
or contexts, but should, in theory, give the patent-holders exclusive
rights to make, use, sell, or import any DNA containing the claimed
15-mers in the United States, including use in research, diagnosis or
other domains. These claims are not, for example, restricted to
sequences actually derived from a BRCA1 sequence, or from human
chromosome 17 (where BRCA1 is located), or only those 15-mers that
are unique to BRCA1, or for use only in the context of risk assessment,
diagnosis, treatment or research on inherited risk of breast and
ovarian cancer. That is, anyone making an “isolated” DNA that
includes any one of the 15 base-pair sequences in the United States
for any purpose would be infringing US patent 5,747,282. The claim
thus covers an inﬁnite number of DNA molecules of variable length if
they contain any of the 1.6 million claimed 15-mer sequences.
To test the practical signiﬁcance of claim 5, we examined the 713
entries in GenBank that represent complete coding sequences for
human mRNAs deposited in 1994 (the year before the patent
application was ﬁled); 568 of these 713 mRNAs (80 percent) contain
at least one BRCA1-derived 15-mer using the restricted codon table.
Note that these mRNA sequences (or cDNAs) are shorter than typical
genes, with a median length of 1902 nucleotides.
These ﬁndings suggest that there were already many sequences in
GenBank covered by claim 5 at the time the patent application was
ﬁled. This further suggests that the claim should not have been
granted, based on section 102 of the Patent Act (novelty). If
challenged by re-examination or in litigation, claim 5 may be deemed
invalid due to readily identiﬁable prior art covered by the claim. The
claim may also be subject to challenge due to insufﬁcient “written
description,” since the sequences are not enumerated in the patent.
It is worth noting that a 1991 patent application for Expressed
Sequence Tags was rejected on several grounds, including the fact that
claimed 15-mer oligonucleotides were found in existing DNA sequences.
This ﬁnding that 15-mers had sequence identity to many genes was
published, and so publicly known by the end of 1992 [8]. That particular
EST patent application was abandoned by NIH in 1994. USPTO examiner
James Martinell estimated at the time that to examine the reach of the
oligonucleotide claims in that patent would have taken until 2035
because of the computational time required to search formatches in over
700,000 15-mers claimed, roughly half the number of molecules covered
by claim5ofMyriad'sUSPatent 5,747,282. Although still computationally
intensive, such sequence comparisons can clearly be done much more
rapidly now. The reason that sequence identity in prior art was not
identiﬁed as a bar to claim 5 by a different examiner for US Patent
5,747,282 when it was being examined between 1995 and 1998 is not
clear in the ‘282 patent's prosecution history (i.e., there is no indication of
a search on 15-mer sequences having been performed in the “ﬁle
wrapper” that records the patent prosecution history) [9].Invalidation of claim 5 would not invalidate other claims in this
patent, or the very broad method claims in other patents, such as
claim 1 of US Patent 5,753,441, assigned to the same parties:
“A method for screening germline of a human subject for an
alteration of a BRCA1 gene which comprises comparing germline
sequence of a BRCA1 gene or BRCA1 RNA from a tissue sample
from said subject or a sequence of BRCA1 cDNA made from mRNA
from said sample with germline sequences of wild-type BRCA1
gene, wild-type BRCA1 RNA or wild-type BRCA1 cDNA, wherein a
difference in the sequence of the BRCA1 gene, BRCA1 RNA or
BRCA1 cDNA of the subject from wild-type indicates an alteration
in the BRCA1 gene in said subject.”
Invalidating claim 5might have little or no effect on the availability
of genetic testing for BRCA sequences in the United States, although it
might prompt the evaluation of other claims in the patents. The
impact of this claim on research is very difﬁcult to assess. The claim
was clearly structured to capture oligonucleotides for hybridization
assays and polymerase chain reaction (PCR)-based diagnostic meth-
ods. The most commonly used diagnostic methods are based on PCR,
which is applied to over 80 distinct segments of the BRCA1 and BRCA2
genes, followed by determination of the sequence of the resulting
amplicons. Such a PCR-based sequencing techniquemight not infringe
the main independent claims 1 and 2 of this patent, although it would
likely be deemed to infringe this claim 5, as well as the method claim
quoted above, and claim 16 of the ‘282 patent:
“A pair of single-stranded DNA primers for determination of a
nuycleotide [sic] sequence of a BRCA1 gene by a polymerase chin
[sic] reaction, the sequence of said primers being derived from
human chromosomne [sic] 17q, wherein the use of said primers in
a polymerase chain reaction results in the synthesis of DNA
having all or part of the sequence of the BRCA1 gene.”
The fate of claim 5 has clear implications, however, if full-genome
sequence analysis becomes feasible, because it would likely be
deemed to be infringed by any form of genomic sequencing, while
other claims of the ‘282 and ‘441 patents would not be (because they
entail cDNA or mRNA steps or PCR amplicons).
The effect of this claimon research is verydifﬁcult to assess. A PubMed
search for the term “BRCA1” returned 7,107 articles. This suggests a large
body of research on the gene has been published in the technical
literature.Myriadhas not enforced its patents againstmost research,with
the exception of laboratories engaged in clinical research that entailed
giving test results to individuals beyond their home institutions [11–13].
Any such research that entailed analysis of DNA molecules containing
BRCA1 sequences in the United States very likely infringed this claim,
however, so enforcement of this claimwould have substantial impact on
research. (Claims to BRCA1 sequences are somewhat narrower in other
English-language jurisdictions such as Canada, Australia and New
Zealand, and a fortiori in Europe, where the claims that emerged from
opposition proceedings were dramatically narrowed.) There is a very
narrow “research exemption” from infringement liability in the United
States under common law, and a broader exemption for research that
results in data contributed to the government for a regulated medical
product or service [14]. Since laboratory-developed tests are not currently
subject to Food and Drug Administration approval, however, this
exemption may not apply.
The simplest conclusion about the effect of claim 5 and Myriad's
other BRCA1 patents on research and clinical testing is that Myriad has
only rarely enforced its patents in research, has vigorously enforced
its patents against commercial genetic testing, and has selectively
enforced its patents in clinical research. It is also apparent that
research on BRCA1 for the past 12 years has entailed massive,
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restricted to BRCA1 research. Any such research in the United States
was thus undertaken under risk of infringement liability and its
associated uncertainty. While Myriad has stated publicly that it has
not enforced its patents against basic research [11,12,15], it has not
stated it will not do so in the future, and therefore BRCA research in
the United States continues only with Myriad's indulgence.
The strategy for claiming DNA sequences exempliﬁed by claim 5 in
‘282 is quite broad. The patent examination manual stipulates that
claims use “the broadest reasonable meaning of the words in their
ordinary usage as theywould be understood by one of ordinary skill in
the art, taking into account whatever enlightenment by way of
deﬁnitions or otherwise that may be afforded by the written
description contained in applicant's speciﬁcation [10].” Lines 14-4
of, column 24 in the patent deﬁne “substantial homology or
similarity” as “nucleotide sequence identity in at least about 60% of
the nucleotide bases,” and deﬁnes “selective hybridization” “when
there is at least about 55% homology over a stretch of at least about 14
nucleotides.” These deﬁnitions explain why 15-mers were chosen, but
do not alter the plain meaning of any of the terms in claim 5. Our
experimental sequence comparisons also meet these deﬁnitions.
Once granted, patent claims are valid until and unless they are
challenged. BRCA patents were cited in enforcement letters that
Myriad Genetics sent to other laboratories to cease genetic testing for
BRCA mutations [11,12].
A judgment in the current BRCA lawsuit is being closely watched
by many for its implications on the practice of clinical genetic testing,
patent practice, and the pursuit of research. The enormously
improved computational capability to examine the reach of partially
ambiguous claims should provide important guidance for those
seeking and granting patents claiming DNA sequences.
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